Main Conference Day One (April 28, 2027) - CET/CEST (Cent Europe Summer, GMT+2)
- Lekan Daramola - Consultant, LD BioConsulting Limited
- Marvin Tanenbaum - Senior Group Leader at Hubrecht Institute & Professor, TU Delft
- Valerie Schmieder - Senior Scientist (CMC Development Biologicals; Drug Substance Biologicals; Cell Line and Upstream Development), Boehringer Ingelheim
Designing upstream feed formulations to intentionally simplify downstream purification steps and reduce COGs.
Navigating current economic pressures (patent cliffs and market competition) through process efficiency gains.
Addressing raw material solubility, metabolism, and batch variability to steer critical quality attributes and ensure robustness.
- Emanuel Kreidl - Senior Expert USP, Novartis
- Nessrine Nefzi - Process Engineer, UCB
Traditional packed-bed resin columns can be major downstream bottlenecks
Improvements when implementing membrane adsorbers vs. resin
Results in buffer reduction, speed
How to implement successfully
- Cornelius Frank - PhD Student – Technical Development Cell & Gene Therapy (PTCG), Roche
- Jesús Lavado-García - Co-PI and Group Leader of the Mammalian Cell and Bioprocess Engineering Group, DTU Biosustain
- Bharat Dixit - Chief Technology Officer, ClearB Therapeutics
The Decision You Rarely Revisit—but Always Pay For
- Denes Zalai - Director Technology, Eleva Biologics
- Adam Brown, Ph.D. - Associate Professor, University of Sheffield
- Bjørn Voldborg - Director CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability
- Vignesh Rajamanickam - Senior Scientist, Boehringer Ingelheim RCV
- Sarah Mattulla - Process Expert - Global Development CMC Biologicals / Bioprocess, Media & Analytics, Boehringer Ingelheim
- Monika Klier - Senior Scientist, BOKU University
- Deekshith Vemireddy - Senior Manager, Downstream Process Development, Alvotech
- Marie Haufroid - ATPS DSP Technologies Senior Scientist, UCB Pharma
- Wei Zhang - Principal Scientist and Group Leader, Bioprocessing Technology Institute (BTI), A*STAR
- Rosario Ramona Martínez García - Head of Process Technologist Group, Plant 1, Molecular Immunology Center (CIM)
Designing analytical approaches to characterise and quantify product variants and impurities.
Setting realistic acceptance criteria for impurities in complex molecules
Linking analytical impurity directly to functional biological activity and potency.
Launching a new innovative solution or looking to drive the conversation? Your expertise belongs on the stage. This high-impact slot is available to showcase late-breaking data, new platform capabilities, or expert case studies to our delegation. Reach out to Partners@informaconnectls.com to get involved!
- Lekan Daramola - Consultant, LD BioConsulting Limited
Moving beyond classical DoE workflows by applying active machine learning algorithms to guide clone screening.
Addressing cell-state heterogeneity and phenotypic drift early during clone evaluation.
Minimizing physical bioreactor runs while predicting long-term productivity and cell health.
- Andy Nelson - Industrial PhD Candidate, AstraZeneca (John Hopkins University)
Utilising specific peptide media additives to steer glycosylation profiles and microheterogeneity during bioreactor runs.
Balancing upstream titre speed against post-translational quality requirements to lock in consistent downstream Drug-to-Antibody Ratios (DAR).
- Karen Wohlers - Head of Bioprocessing, Bluu
- Friederike Elits - Group Manager Bioprocess Engineering DSP, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
- Wei Zhang - Principal Scientist and Group Leader, Bioprocessing Technology Institute (BTI), A*STAR
- Achraf Jazi - Senior Product Manager, Asahi Kasei Bioprocess Europe
- Shifting from transient transfection to stable producer cell lines
- Overcoming the 70% downstream yield loss wall for lentivirus/LNPs
- Addressing the reimbursement crisis via platform manufacturing
- How much change to COGs will automation truly bring?
Launching a new innovative solution or looking to drive the conversation? Your expertise belongs on the stage. This high-impact slot is available to showcase late-breaking data, new platform capabilities, or expert case studies to our delegation. Reach out to Partners@informaconnectls.com to get involved!
- Kat Kozyrytska - Founder, Cell Therapy Manufacturability Program
Structuring regulatory packages for accelerated approval pathways across ADCs, radiotherapies, and complex formats.
Developing holistic control strategies and resolving regulatory roadblocks during late-stage filings.
Translating technical risk evaluations into actionable strategies that satisfy FDA/EMA expectations.
Launching a new innovative solution or looking to drive the conversation? Your expertise belongs on the stage. This high-impact slot is available to showcase late-breaking data, new platform capabilities, or expert case studies to our delegation. Reach out to Partners@informaconnectls.com to get involved!
- Raja Amasheh - Global Head of Material Compliance, Safety & Sustainability, Roche